0384103 - ÚMCH 2013 RIV GB eng J - Článek v odborném periodiku
Talelli, M. - Oliveira, S. - Rijcken, C. J. F. - Pieters, E. H. E. - Etrych, Tomáš - Ulbrich, Karel - van Nostrum, R. C. F. - Storm, G. - Hennink, W. E. - Lammers, T.
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy.
Biomaterials. Roč. 34, č. 4 (2013), s. 1255-1260. ISSN 0142-9612. E-ISSN 1878-5905
Grant CEP: GA AV ČR IAA400500806; GA ČR GAP301/11/0325
Výzkumný záměr: CEZ:AV0Z40500505
Klíčová slova: polymeric micelle * doxorubicin * active targeting
Kód oboru RIV: CD - Makromolekulární chemie
Impakt faktor: 8.312, rok: 2013 ; AIS: 1.965, rok: 2013
DOI: https://doi.org/10.1016/j.biomaterials.2012.09.064

Various different passively and actively targeted nanomedicines have been designed and evaluated over the years, in particular for the treatment of cancer. Reasoning that the potential of ligand-modified nanomedicines can be substantially improved if intrinsically active targeting moieties are used, we have here set out to assess the in vivo efficacy of nanobody-modified core-crosslinked polymeric micelles containing covalently entrapped doxorubicin. Nanobody-modified polymeric micelles were found to inhibit tumor growth even in the absence of a drug, and nanobody-modified micelles containing doxorubicin were significantly more effective than nanobody-free micelles containing doxorubicin. Based on these findings, we propose that the combination of two therapeutic strategies within one nanomedicine formulation, i.e. the intrinsic pharmacological activity of ligand-modified carrier materials with the cytostatic activity of the incorporated chemotherapeutic agents, is a highly promising approach for improving the efficacy of tumor-targeted combination therapy.
Trvalý link: http://hdl.handle.net/11104/0217252